The two Research Projects and Transport Oncophysics Core (TOC) of the proposed Center for Immunotherapeutic Transport Oncophysics (CITO) form a collaborative and cohesive program to determine and understand the transport of immune cells, molecules, and particles, through systemic circulation and within the tumor microenvironment, and to exploit these features for the rational design of effective cancer immunotherapies and vaccines for breast and pancreatic cancers. To achieve this overarching goal, we recognize the need to foster current and future generations of individuals with a distinctive and powerful combination of transdisciplinary knowledge and skill sets in physical sciences oncology and the commitment to sharing and exploring this emerging domain with the scientific and lay communities. The Education and Outreach Unit (EOU) will promote the education and development of faculty, trainees, students, and advocates within the CITO. It will also serve as the mechanism for CITO members to engage with other Physical Sciences-Oncology Centers (PS-OCs), the broader scientific community, and the public, and to disseminate information and concepts on the physical sciences in cancer research and patient care. Detailed descriptions of planned programs and activities can be found in the EOU component of this application; we also summarize them in the Administrative Core (AC) component. We will organize several types of programs and activities that are intended to: 1) bring in new expertise and perspectives on physical sciences oncology (conferences, seminars, workshops, public engagement forums); 2) offer trainees and students avenues for interactive, laboratory- and/or clinic-based education in physical sciences oncology (fast-track research opportunities); 3) enable CITO investigators to take a sabbatical to other Physical Sciences-Oncology Network (PS-ON) laboratories as part of cross-training opportunities; 4) disseminate information to the public on the ideas, technologies, and capabilities of physical sciences oncology, and its potential impact on cancer research and patient care (via the Community Engagement Program with our patient advocates); and 5) gather relevant information and feedback from the patient community and the general public that would continue to guide and drive the CITO's research, educational, and outreach activities. The AC is charged with managing and facilitating activities for the EOU. Dr. Mauro Ferrari (CITO Principal Investigator, PI) will set the programmatic framework for the EOU, which will align with the thematic elements of the CITO Projects and TOC. He and the three other AC Co-Leaders (Dr. Elizabeth Mittendorf, Dr. Rongfu Wang, and Dr. Rolf Brekken) will lend strategic direction for the overall activities of the EOU, and the Center Administrator, Dr. Hanh Hoang, and staff will support them in implementing and coordinating those activities based on the requirements outlined by the CITO and the PS-ON.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA210181-03
Application #
9534565
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Methodist Hospital Research Institute
Department
Type
DUNS #
185641052
City
Houston
State
TX
Country
United States
Zip Code
77030
Nizzero, Sara; Ziemys, Arturas; Ferrari, Mauro (2018) Transport Barriers and Oncophysics in Cancer Treatment. Trends Cancer 4:277-280
Du, Wenting; Huang, Huocong; Sorrelle, Noah et al. (2018) Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. JCI Insight 3:
Tang, Chad; Hobbs, Brian; Amer, Ahmed et al. (2018) Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep 8:1922
Liu, Haoran; Mai, Junhua; Shen, Jianliang et al. (2018) A Novel DNA Aptamer for Dual Targeting of Polymorphonuclear Myeloid-derived Suppressor Cells and Tumor Cells. Theranostics 8:31-44
Wang, Feng; Xia, Xiaojun; Yang, Chunying et al. (2018) SMAD4 Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy through Promotion of Autophagy. Clin Cancer Res 24:3176-3185
Kojic, M; Milosevic, M; Kojic, N et al. (2018) Mass release curves as the constitutive curves for modeling diffusive transport within biological tissue. Comput Biol Med 92:156-167
Zhu, Motao; Ding, Xilai; Zhao, Ruifang et al. (2018) Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma. J Control Release 272:72-82
Du, Wenting; Brekken, Rolf A (2018) Does Axl have potential as a therapeutic target in pancreatic cancer? Expert Opin Ther Targets 22:955-966
Koay, Eugene J; Lee, Yeonju; Cristini, Vittorio et al. (2018) A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24:5883-5894
Koay, Eugene J; Owen, Dawn; Das, Prajnan (2018) Radiation-Induced Liver Disease and Modern Radiotherapy. Semin Radiat Oncol 28:321-331

Showing the most recent 10 out of 31 publications